Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Liabilities and Shareholders Equity (2016 - 2025)

Rein Therapeutics filings provide 10 years of Liabilities and Shareholders Equity readings, the most recent being $24.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 61.15% year-over-year to $24.2 million, compared with a TTM value of $193.0 million through Dec 2025, down 48.54%, and an annual FY2025 reading of $24.2 million, down 61.15% over the prior year.
  • Liabilities and Shareholders Equity hit $24.2 million in Q4 2025 for Rein Therapeutics, down from $53.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $109.4 million in Q2 2024, with the low at $12.8 million in Q3 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $54.2 million (2021), compared with a mean of $53.5 million.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 712.8% in 2024, then tumbled 61.15% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $48.5 million in 2021, then crashed by 54.61% to $22.0 million in 2022, then soared by 381.7% to $106.0 million in 2023, then tumbled by 41.33% to $62.2 million in 2024, then plummeted by 61.15% to $24.2 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $24.2 million, $53.7 million, and $57.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.